Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | PARG | Q86W56 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192046 | 0.94 | KDM4E (0.54) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL2192047 | 0.94 | KDM4E (0.54) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL14485052 | 0.92 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL29955891 | 0.88 | KDM4E (0.51) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL3416562 | 0.82 | KDM4E (0.45) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL3416565 | 0.82 | KMT2A (0.59) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL520306 | 0.81 | ALDH1A1 (0.60) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL29954983 | 0.81 | ALDH1A1 (0.60) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL8355420 | 0.79 | KDM4E (0.67) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A | |
| SCHEMBL2225334 | 0.79 | KDM4E (0.67) | SMN1; SMN2KDM4ERECQLALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106636043-B | Method for producing protease | 广州立白企业集团有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-10709706-B2 | Nuclear transport modulators and uses thereof | Karopharm Therapeutics Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709706-B2 | Nuclear transport modulators and uses thereof | Karopharm Therapeutics Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| CN-106636043-B | Method for producing protease | 广州立白企业集团有限公司 | 2020-04-07 | — | — | CN | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190160063-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-05-30 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | disclosed |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2035372-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008005338-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SMN1; SMN2 2748/4885KDM4E 2926/4885RECQL 2063/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | SMN1; SMN2 4487/4885KDM4E 2740/4885RECQL 2523/4885 |
| US-10709706-B2 | Nuclear transport modulators and uses thereof | XPO5, XPO1, XPOT | SMN1; SMN2 437/4885KDM4E 2258/4885RECQL 324/4885 |
| US-20190160063-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO5, XPO1, XPOT | SMN1; SMN2 437/4885KDM4E 2258/4885RECQL 324/4885 |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SMN1; SMN2 2748/4885KDM4E 2926/4885RECQL 2063/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | SMN1; SMN2 2179/4885KDM4E 1021/4885RECQL 466/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | SMN1; SMN2 4746/4885KDM4E 3363/4885RECQL 1042/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | SMN1; SMN2 3419/4885KDM4E 2801/4885RECQL 1863/4885 |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | PI4KA, PIK3CA, PIK3CB | SMN1; SMN2 4569/4885KDM4E 866/4885RECQL 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.